|Videos|July 7, 2016

The Impact of PCSK9 Inhibitors on Specialty Pharmacy

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME